Search Results

Protara is advancing a cell therapy that triggers both adaptive and innate antitumor immune responses, while CG Oncology’s approach makes use of an oncolytic immunotherapy that preferentially targets cancer cells and proliferates inside them, destroying them from the inside.

CG Oncology, Inc. announced that it has initiated an Expanded Access Program for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette-Guerin and meet certain program eligibility criteria.

Following an upsized IPO earlier this year, CG Oncology on Friday posted promising Phase III data for cretostimogene, which elicited a 75% complete response rate in high-risk non-muscle invasive bladder cancer patients.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, reported financial results for the first quarter ended March 31, 2024, and provided business updates.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.

CG Oncology, Inc. announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL.